Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Deleobuvir: Additional Phase IIb data

Additional data from the open-label, international Phase IIb SOUND-C3 trial showed that 19 of 20 (95%) evaluable treatment-naïve patients with chronic HCV genotype 1b infection who received once-daily faldaprevir (BI 201335) plus twice-daily deleobuvir (BI

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers